Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

Mostrar otras versiones (1)

<h4>Background</h4> We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. <h4>Methods and findings</h4> In this randomised, observer...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Houreratou Barry, Gaudensia Mutua, Hannah Kibuuka, Zacchaeus Anywaine, Sodiomon B. Sirima, Nicolas Meda, Omu Anzala, Serge Eholie, Christine Bétard, Laura Richert, Christine Lacabaratz, M. Juliana McElrath, Stephen De Rosa, Kristen W. Cohen, Georgi Shukarev, Cynthia Robinson, Auguste Gaddah, Dirk Heerwegh, Viki Bockstal, Kerstin Luhn, Maarten Leyssen, Macaya Douoguih, Rodolphe Thiébaut, the EBL2002 Study group
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Medicine
R
Acceso en línea:https://doaj.org/article/7f50b4c25b664eea9599a273130f7e74
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/7f50b4c25b664eea9599a273130f7e74

Ejemplares similares